Albireo to participate in h.c. wainwright 3rd annual hepatitis b virus (hbv) conference

Boston, oct. 12, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the wainwright 3rd annual hepatitis b virus (hbv) conference on october 18, 2022. albireo will be presenting and will host investor meetings.
ALBO Ratings Summary
ALBO Quant Ranking